2020 William Donald Nash Brain Tumour Research Fellowship Recipient

Nicholas Mikolajewicz

Postdoctoral Researcher
Terrence Donnelly Centre for Cellular & Biomolecular Research
University of Toronto

Project Title: “Identifying transcriptional drivers of glioblastoma heterogeneity”

Brief summary of research:

Glioblastoma Multiforme (GBM) remains an incurable brain cancer, largely due to its ability to transition and co-exist between multiple distinct states within individual patient tumours. Resistant GBM subpopulations are capable of evading immunotherapy and result in aggressive recurrent tumours with poor clinical outcomes. This project will use a combination of bioinformatic and genetic tools to identify gene expression regulators in GBM cells (i.e., transcription factors) that enable the reprogramming of heterogenous GBM tumours into uniform states that are responsive to immunotherapy. Candidate transcription factors that control the transition of GBM between different cell states will be identified using (i) a combination of single-cell transcriptomics and bioinformatics to map GBM-subtype-specific gene expression patterns to known gene regulators, and (ii) genome-wide CRISPR screens to identify genes that influence GBM immune resistance. GBM cells will then be genetically-engineered to disrupt the functions of candidate transcription factors to identify specific genetic perturbation that reprogram GBM cells into uniform cells states for each GBM subtype. Ultimately, the growth of reprogrammed GBM tumours in mice receiving tumour-targeting T-cell transfers will be evaluated. This work will provide novel insights into the drivers of GBM heterogeneity and explore whether reprogramming GBM tumours can lead to better immunotherapy outcomes.

What receiving this award means to you:

Being awarded the William Donald Nash Brain Tumour Research Fellowship will allow me to develop an exciting project in glioblastoma that addresses one of the greatest challenges in cancer treatment: How do we treat something that actively evades conventional and emerging treatments? Emerging single-cell genomic technologies make this an exciting time for cancer research, as they provide tools to glimpse into tumor heterogeneity and complexity at an unpreceded single cell-level resolution. Over the term of this fellowship I will develop and apply these technologies to identify novel molecular targets that will reprogram glioblastomas to different states, with the aim being to sensitize these tumors to existing and emerging treatments. As a postdoctoral fellow, this fellowship is an incredible opportunity to develop my own ideas and apply my interdisciplinary training in statistics, cellular biology and single-cell genomics to the complexities presented by glioblastoma. As a medical student, my excitement for this project cannot be overstated as the support of this fellowship sets the stage for me to develop my eventual findings into novel and exciting therapies as a clinician scientist. I am grateful to the Nash Family and the Brain Tumour Foundation of Canada for this generous opportunity, and for supporting my aspirations towards becoming a clinician scientist.

Progress Update: August, 2021

Two distinct mouse models of glioblastoma, CT2A and GL261, were engrafted into mouse brains and subsequently profiled using single-cell transcriptomics to obtain high-resolution data characterizing the tumor and surrounding microenvironment. Using this approach, we found that the mouse tumors recapitulated similar degrees of diversity as seen in patient tumors, thereby demonstrating the validity of these mouse models. Then using a collection of public and in-house GBM datasets profiled using the same single-cell transcriptomic platform, we applied machine-learning methods to nominate candidate transcription factors that regulate GBM subtypes. Four candidate transcription factors were selected for experimental validation and we are currently in the process of generating CRISPR-Cas9-mediated knockout cell lines that will eventually be engrafted and characterized in our validated mouse models. These experiments are expected to provide insight into how GBM subtypes are affected following genetic perturbation of various transcription factors, and whether a uniform state that is more responsive to therapy can be achieved.

Progress Update: August, 2022

Layman Summary of Progress (2021-2022)
Fellowship Progress Report (2021-2022)